Beljaards Rob C, de Roos Kees-Peter, Bruins Frank G
Department of Dermatology, Kennemer Gasthuis, Haarlem, The Netherlands.
Dermatol Surg. 2005 Jul;31(7 Pt 1):772-6; discussion 776.
New injectable materials for skin augmentation that promise to be the ideal filling material are introduced every year. Recently, we treated three patients with adverse reactions to a new substance for skin augmentation: polylactic acid (NewFill, Ashford Aesthetics Inc, Belgium).
To present three cases in which serious adverse reactions had occurred after skin augmentation with a new filling substance, polylactic acid (NewFill). Because an identical substance (Sculptra, Aventis Pharmaceuticals, Bridgewater, NJ, USA) was recently introduced in the United States, we want to alert future users of these substances to possible adverse events.
We report three cases with serious adverse events more than 12 months after skin augmentation with polylactic acid (NewFill). They were treated with intralesional steroid therapy and topical imiquimod application.
Both intralesional steroid therapy and topical imiquimod application lead to moderate results. If feasible, surgical excision is the best available option.
Great care should be taken when polylactic acid is used for intradermal injection because giant cell granulomatous reactions may be the result. Other than surgical excision, effective treatment options are lacking.
每年都会推出有望成为理想填充材料的新型皮肤填充注射材料。最近，我们治疗了三名对一种新型皮肤填充物质——聚乳酸（NewFill，比利时阿什福德美学公司）出现不良反应的患者。
介绍三例使用新型填充物质聚乳酸（NewFill）进行皮肤填充后发生严重不良反应的病例。由于美国最近引入了一种相同的物质（塑然雅，美国新泽西州布里奇沃特安万特制药公司），我们希望提醒这些物质的未来使用者可能出现的不良事件。
我们报告三例使用聚乳酸（NewFill）进行皮肤填充12个月后发生严重不良事件的病例。对其采用皮损内注射类固醇疗法和外用咪喹莫特治疗。
皮损内注射类固醇疗法和外用咪喹莫特治疗均取得了中等效果。若可行，手术切除是最佳选择。
使用聚乳酸进行皮内注射时应格外小心，因为可能会导致巨细胞肉芽肿反应。除手术切除外，缺乏有效的治疗选择。
